Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

GNPAT p.D519G is Independently Associated with Markedly Increased Iron Stores in HFE p.C282Y Homozygotes

James C. Barton, MD, Wen-Pin Chen, MS, Mary J. Emond, PhD, Pradyumna D. Phatak, MD, V. Nathan Subramaniam, PhD, Paul C. Adams, MD, Lyle C. Gurrin, PhD, Gregory J. Anderson, BSc, MSc, PhD, Grant A. Ramm, PhD, Lawrie W. Powell, MD, PhD, Katrina J. Allen, FRACP, MD PhD, John D. Phillips, PhD, Charles J. Parker, MD, Gordon D. McLaren, MD, Christine E. McLaren, PhD

Blood (2016) 128 (22): 3617.

https://doi.org/10.1182/blood.V128.22.3617.3617

Published: 2016

Journal Articles

Exome Sequencing Identifies a GNPAT Variant Associated with Severe Iron Overload in HFE C282Y Homozygous Men with Extreme Phenotypes; Possible Role in Regulation of Hepcidin Expression

Gordon D. McLaren, MD, Mary J. Emond, PhD, V. Nathan Subramaniam, PhD, Pradyumna D. Phatak, MD, James C. Barton, MD, Paul C. Adams, MD, Justin B. Goh, PhD, Cameron J. McDonald, PhD, Lawrie W. Powell, MD PhD, Lyle C. Gurrin, PhD, Katrina J. Allen, MBBS, PhD, Deborah A. Nickerson, PhD, Tin Louie, MS, Grant A. Ramm, PhD, Gregory J. Anderson, PhD, Christine E. McLaren, PhD

Blood (2014) 124 (21): 745.

https://doi.org/10.1182/blood.V124.21.745.745

Published: 2014

Journal Articles

Exome Sequencing Identifies Genes and Variant Alleles Associated With Severity Of Iron Overload In Hemochromatosis HFE C282Y Homozygotes

Christine E. McLaren, PhD, Mary J. Emond, PhD, Pradyumna D. Phatak, MD, Paul C. Adams, MD, V. Nathan Subramaniam, PhD, James C. Barton, MD, Lawrie W. Powell, MD, PhD, Lyle C. Gurrin, PhD, Katrina J. Allen, MBBS, PhD, Deborah A. Nickerson, PhD, Tin Louie, MS, Grant A. Ramm, PhD, Gregory J. Anderson, PhD, Gordon D. McLaren, MD

Blood (2013) 122 (21): 179.

https://doi.org/10.1182/blood.V122.21.179.179

Published: 2013

Journal Articles

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

A. Pietrangelo, MD, PhD, P. Brissot, MD, H. Bonkovsky, MD, C. Niederau, L. Rojkjaer, R. Weitzman, J. Bodner, S. Bailey, Pradyumna D. Phatak, MD

Blood (2007) 110 (11): 2680.

https://doi.org/10.1182/blood.V110.11.2680.2680

Published: 2007

Journal Articles

Elevated MCV in Patients with Hereditary Hemochromatosis.

Sameh E. Mikhail, MD, Pradyumna D. Phatak, MD

Blood (2006) 108 (11): 3733.

https://doi.org/10.1182/blood.V108.11.3733.3733

Published: 2006

Journal Articles

Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.

Thomas E. Delea, MSIA, Oleg Sofrygin, MS, Jean-Francois Baladi, MBA, Simu K. Thomas, PhD, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 3134.

https://doi.org/10.1182/blood.V106.11.3134.3134

Published: 2005

Journal Articles

Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.

Thomas E. Delea, MSIA, May Hagiwara, PhD, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 5583.

https://doi.org/10.1182/blood.V106.11.5583.5583

Published: 2005

Journal Articles

Cost-Effectiveness Analysis of Oral Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Chelation Therapy with Deferoxamine in Patients with Transfusion-Dependent Myelodysplastic Syndrome.

Thomas E. Delea, MSIA, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD

Blood (2005) 106 (11): 5585.

https://doi.org/10.1182/blood.V106.11.5585.5585

Published: 2005

Journal Articles

Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.

Thomas E. Delea, MSIA, Oleg Sofrygin, MS, Simu K. Thomas, PhD, Jean-Francois Baladi, MBA, Pradyumna D. Phatak, MD, Thomas D. Coates, MD

Blood (2005) 106 (11): 1341.

https://doi.org/10.1182/blood.V106.11.1341.1341

Published: 2005

NARROW

GNPAT p.D519G is Independently Associated with Markedly Increased Iron Stores in HFE p.C282Y Homozygotes

Exome Sequencing Identifies a GNPAT Variant Associated with Severe Iron Overload in HFE C282Y Homozygous Men with Extreme Phenotypes; Possible Role in Regulation of Hepcidin Expression

Exome Sequencing Identifies Genes and Variant Alleles Associated With Severity Of Iron Overload In Hemochromatosis HFE C282Y Homozygotes

Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH).

Elevated MCV in Patients with Hereditary Hemochromatosis.

Costs and Consequences of Inadequate Compliance with Deferoxamine Therapy in Patients with Transfusion-Dependent Thalassemia.

Utilization and Costs of Deferoxamine in Patients with Thalassemia, Sickle-Cell Disease, or Myelodysplastic Syndrome Receiving Frequent Transfusions.

Cost-Effectiveness Analysis of Oral Iron Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Chelation Therapy with Deferoxamine in Patients with Transfusion-Dependent Myelodysplastic Syndrome.

Cost-Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine in Transfusion-Dependent Thalassemic Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only